MENINGIOMA

MENINGIOMA

Primary Disciplinary Field(s): Neurology, Neurosurgery, Oncology, Pathology

1. Core Definition

Meningioma is defined as a primary central nervous system (CNS) tumor that arises from the meninges, the protective layers covering the brain and spinal cord. Specifically, these tumors originate from the arachnoid cap cells, which are specialized cells residing within the arachnoid mater—the middle layer of the three meningeal membranes (dura mater, arachnoid mater, and pia mater). Meningiomas represent the most frequently diagnosed primary intracranial tumors, excluding pituitary and pineal tumors, accounting for a significant proportion of CNS neoplasms in the adult population. Historically and clinically, the majority of meningiomas are classified as benign (WHO Grade I) tumors, meaning they are non-cancerous, slow-growing, and typically do not metastasize to distant sites, aligning with the initial classification provided in medical literature.

The distinction between meningiomas and other brain tumors is crucial, as their cellular origin dictates their biological behavior and overall prognosis. Unlike gliomas, which arise from glial support cells within the brain parenchyma itself, meningiomas grow externally to the brain tissue. They are characterized by their slow, expansive growth pattern, pushing against the adjacent brain structures rather than infiltrating them. This characteristic growth pattern is essential to understanding the symptomatology and surgical approach, as the tumor’s pressure leads to neurological deficits. Even though the tumor itself is usually benign, its location and size within the confined space of the skull mean that it can cause severe morbidity or mortality simply due to this continuous, unrelenting pressure exerted upon vital neural structures.

Epidemiological data confirm the prevalence of this condition, noting that meningiomas are responsible for approximately 15% to 25% of all primary brain tumors diagnosed annually, making them a major area of focus within neuro-oncology. The term meningioma itself highlights its origin, combining the root “meninges” with the suffix “-oma,” meaning tumor or mass. Due to their tendency for slow progression, these tumors often remain asymptomatic for long periods, sometimes being discovered incidentally during imaging performed for unrelated health issues. However, when symptoms do manifest, they are typically a direct result of the mass effect, necessitating careful diagnosis and tailored therapeutic strategies.

2. Clinical Characteristics and Epidemiology

The clinical presentation of a meningioma is highly variable and depends critically on the tumor’s size, growth rate, and precise location within the CNS. Because most meningiomas grow slowly over years or even decades, the body often adapts to the gradual increase in intracranial pressure. Consequently, initial symptoms may be vague, such as non-specific headaches, or may only present when the tumor reaches a substantial size or begins to impinge directly upon eloquent areas of the brain, such as the motor cortex or optic nerves. Common focal symptoms include seizure activity, which results from cortical irritation, progressive weakness or sensory changes in limbs, and visual disturbances like diplopia or visual field cuts if the tumor affects the optic pathways.

Meningiomas predominantly affect older individuals, with incidence rates increasing significantly after the fifth decade of life and peaking in the 60s and 70s. A notable characteristic of meningioma epidemiology is the pronounced gender bias. Studies consistently show a higher incidence rate in women compared to men, particularly for non-skull base tumors. This observation has led to extensive research into the role of hormonal influence, specifically the presence of progesterone and, to a lesser extent, estrogen receptors within the tumor cells. This hormonal connection supports the clinical finding that some meningiomas may grow or become symptomatic during pregnancy or during exogenous hormone therapy, suggesting a mechanism distinct from many other forms of CNS malignancies.

The classification of meningiomas based on their location is critical, as tumors arising from different sites—such as the cerebral convexities, the falx cerebri, the skull base (e.g., sphenoid wing, olfactory groove, or petroclival region), or the spinal cord—present unique challenges regarding surgical accessibility and resulting neurological risk. Convexity meningiomas, which grow on the surface of the brain, are often easier to resect entirely but are more likely to cause seizures. In contrast, skull base meningiomas, while often exhibiting a slower growth pattern, are intimately associated with critical cranial nerves and major blood vessels, making complete surgical removal hazardous and often resulting in complex post-operative deficits.

The core characteristic emphasized in the source material—that meningiomas typically grow slowly—is the key determinant of long-term patient management. This protracted natural history allows clinicians the option of non-aggressive management, known as watchful waiting or active surveillance, for many small, asymptomatic lesions, especially in older patients or those with significant comorbidities. Regular magnetic resonance imaging (MRI) is used during surveillance to monitor the tumor volume and growth kinetics. However, even slow growth, when sustained, will eventually necessitate intervention if the tumor’s volume threatens critical neurological function or causes debilitating symptoms due to the pressure exerted on the brain.

3. Classification and Grading

The definitive classification and prognosis of meningiomas rely heavily on the histological findings defined by the World Health Organization (WHO) classification system for CNS tumors. This system assigns a grade from I to III, which correlates directly with the tumor’s propensity for aggressive behavior, cellular atypia, mitotic activity, and risk of recurrence. Accurate grading is paramount for determining the necessity and intensity of post-operative adjuvant therapies, such as radiation. The majority of meningiomas fall into the lowest grade, reinforcing the notion of them as largely benign entities.

WHO Grade I Meningioma: This grade encompasses approximately 80% to 90% of all diagnosed meningiomas and is considered benign. These tumors exhibit a low mitotic index, minimal cellular atypia, and a low risk of recurrence following gross total resection. Common histological subtypes within Grade I include meningothelial, fibrous (fibroblastic), transitional (mixed), psammomatous, and microcystic meningiomas. Patients with Grade I tumors generally have an excellent long-term prognosis, with five-year survival rates exceeding 90%. The goal of treatment for these lesions is curative resection, often eliminating the need for further intervention.

WHO Grade II Meningioma: Classified as atypical, Grade II meningiomas exhibit intermediate aggressiveness. They are defined by specific histological features, including increased mitotic activity (typically four to nineteen mitoses per ten high-power fields), necrosis, high cellularity, or invasion into the adjacent brain parenchyma. Atypical meningiomas have a significantly higher rate of recurrence compared to Grade I tumors, even after seemingly complete surgical removal. Due to this heightened risk, adjuvant radiation therapy is frequently recommended following surgical resection of Grade II lesions, particularly if subtotal resection was achieved, or if the tumor location suggests a high risk of relapse.

WHO Grade III Meningioma: These are the malignant, or anaplastic, meningiomas, representing the rarest but most aggressive subset. Grade III tumors show overtly malignant cytological features, a very high mitotic rate (twenty or more mitoses per ten high-power fields), and often aggressive brain invasion. Anaplastic meningiomas behave similarly to high-grade malignant gliomas, demonstrating a high propensity for rapid recurrence and, occasionally, for distant metastasis outside the CNS. The prognosis for Grade III meningiomas is poor, despite aggressive multimodal treatment involving maximal safe surgical resection followed by high-dose fractionated radiotherapy. Current research is heavily focused on identifying effective systemic therapies, such as targeted agents or immunotherapy, to improve outcomes for this highly challenging group of patients.

4. Pathogenesis and Risk Factors

The etiology of meningiomas is multifactorial, involving a complex interplay of genetic predisposition, hormonal influences, and environmental exposure. The most commonly identified genetic aberration linked to sporadic (non-inherited) meningiomas involves mutations in the Neurofibromatosis type 2 (NF2) gene, located on chromosome 22. The NF2 gene codes for a tumor suppressor protein called merlin (or schwannomin). Loss-of-function mutations in NF2 lead to dysregulation of cell growth and proliferation, particularly in the arachnoid cap cells, initiating meningioma formation. While NF2 mutations are strongly associated with meningioma development, they are typically found in lower-grade tumors and in those located on the cerebral convexities, whereas skull base tumors often involve different mutational pathways.

The previously mentioned gender predilection strongly implicates endocrine factors in the pathogenesis of meningiomas. Tumor tissue analysis frequently reveals high levels of progesterone receptors (PR), and sometimes estrogen receptors (ER), leading to the hypothesis that endogenous or exogenous hormones can act as promoters for tumor growth. This theory is supported by clinical observations that meningiomas often grow more rapidly during periods of high hormonal activity, such as pregnancy, or in patients receiving hormonal replacement therapy. Consequently, hormonal manipulation, such as the use of progesterone receptor antagonists, has been explored as a potential therapeutic avenue, although efficacy in established tumors remains limited compared to surgical or radiotherapeutic options.

Beyond genetic and hormonal factors, the only consistently proven environmental risk factor for meningioma development is prior exposure to ionizing radiation. This risk is most pronounced in individuals who received high-dose cranial irradiation, often for childhood malignancies like tinea capitis or other head and neck conditions. The latency period between radiation exposure and meningioma development can be decades long, and radiation-induced meningiomas often present as multiple lesions and may carry a slightly higher risk of atypical or malignant transformation compared to sporadic cases. Other potential, though less clearly established, risk factors include obesity and certain immune deficiencies, suggesting a broad spectrum of inputs contributing to the initiation and progression of this tumor type.

5. Diagnosis and Imaging

The diagnostic process for meningioma typically begins with neuroimaging, following the onset of neurological symptoms or the incidental discovery of a mass during routine screening. Magnetic Resonance Imaging (MRI) is the gold standard modality, providing superior soft tissue contrast and detailed anatomical information necessary for surgical planning. Computed Tomography (CT) scans are useful for assessing associated changes in the skull bone, such as hyperostosis (thickening of the bone adjacent to the tumor) or erosion, and for initial detection of calcified lesions, but they lack the resolution of MRI for evaluating the tumor-brain interface.

On MRI, meningiomas exhibit several characteristic features that aid in presumptive diagnosis. These tumors typically appear as well-circumscribed, extra-axial masses (meaning they are outside the brain parenchyma). They demonstrate homogeneous enhancement following the administration of intravenous gadolinium contrast, a result of the tumor’s increased vascularity and the breakdown of the blood-brain barrier at the dural surface. A hallmark feature, though not pathognomonic (exclusive), is the “dural tail sign,” which refers to the linear enhancement of the dura mater extending away from the tumor margin, representing reactive changes in the dura surrounding the main tumor body.

Advanced imaging sequences provide further crucial information. Magnetic resonance spectroscopy (MRS) can help differentiate meningiomas from other masses like schwannomas or metastases by demonstrating specific metabolite profiles. Angiography or MR venography may be employed, especially for large tumors or those located near major venous sinuses, to assess vascular supply and the degree of dural venous sinus invasion. This vascular information is critical for neurosurgeons, as meningiomas often derive a substantial blood supply from the external carotid artery branches, which must be managed during resection to minimize bleeding risk.

While imaging provides a highly accurate presumptive diagnosis, the definitive classification into WHO Grades I, II, or III, and the identification of specific histological subtypes, requires tissue sampling. Therefore, diagnosis is confirmed through histopathological examination of tissue obtained during surgical resection or biopsy. Pathologists analyze the cellular morphology, look for features of atypia, and count the mitotic rate to assign the final grade, which guides all subsequent treatment decisions and defines the long-term prognosis for the patient.

6. Treatment Modalities

The management strategy for meningiomas is highly individualized, dictated by the tumor’s size, location, WHO grade, the patient’s age, and their overall clinical status. Treatment options range from observation to aggressive multimodal therapy involving surgery and radiation. The fundamental goal, particularly for symptomatic or growing tumors, is effective disease control with the preservation of neurological function.

For small, asymptomatic meningiomas, especially in older patients or those with multiple medical comorbidities where surgical risks outweigh the potential benefits, active surveillance is the preferred approach. This involves periodic clinical examinations and surveillance imaging (typically MRI every 6 to 12 months) to monitor growth. Intervention is reserved for cases where the tumor demonstrates documented growth or begins to cause new or worsening symptoms. This conservative approach acknowledges the typical benign, slow-growing nature of the majority of these tumors.

Surgical resection remains the primary curative treatment for accessible, symptomatic, or high-grade meningiomas. The neurosurgical objective is maximal safe resection, striving for a gross total removal whenever possible. The extent of resection is the single most important factor determining the likelihood of recurrence for Grade I tumors. Surgeons often use the Simpson Grading System (Grade I through V) to classify the completeness of removal, which inversely correlates with the risk of recurrence. Simpson Grade I removal (gross total resection including the underlying affected dura and bone) yields the lowest recurrence risk, while Grade V (biopsy only) carries the highest. Difficult locations, particularly the skull base, often necessitate subtotal resection (Simpson Grade IV) to protect critical neurovascular structures, leading to a higher dependence on adjuvant therapy.

Radiation therapy plays a crucial role both as a primary treatment option for unresectable tumors and as an adjuvant therapy following subtotal resection or for higher-grade lesions (Grade II and III). Stereotactic Radiosurgery (SRS) is commonly used for smaller, well-defined tumors that are either recurrent or located in challenging anatomical areas, delivering a high, precise dose of radiation in one or a few fractions. Fractionated external beam radiation therapy is generally reserved for larger tumors, residual disease after subtotal resection, or for Grade II and III tumors where a larger target volume needs to be treated to sterilize potentially microscopic disease and reduce the high risk of recurrence associated with these grades.

7. Prognosis and Follow-up

The long-term prognosis for a patient diagnosed with meningioma is highly dependent on the WHO histological grade and the success of initial treatment. Patients with Grade I meningiomas who achieve a Simpson Grade I (complete) resection have an excellent prognosis, with recurrence rates well under 10% over ten years. Even after subtotal resection of Grade I tumors, the recurrence rate remains manageable, often requiring only surveillance or subsequent focused radiation therapy upon evidence of growth. The benign classification means that the primary concern is local control rather than systemic spread.

In contrast, patients with Grade II (atypical) and especially Grade III (anaplastic) meningiomas face a significantly more guarded prognosis. Grade II tumors exhibit recurrence rates as high as 30% to 50% within five years, even with multimodal treatment. Grade III tumors have recurrence rates exceeding 80%, and their overall prognosis is poor, with average survival times measured in just a few years. For these higher grades, tumor biology, rather than just surgical extent, becomes the primary determinant of outcome, leading to the necessary integration of adjuvant radiation and, increasingly, participation in clinical trials exploring novel systemic agents.

Lifelong follow-up and surveillance imaging are mandatory for all meningioma patients, regardless of the initial grade or perceived completeness of resection. Because meningiomas can recur many years after initial treatment, often peaking in recurrence risk around 5 to 10 years post-surgery, patients undergo regular MRI scans. The frequency of surveillance decreases over time but rarely ceases entirely, particularly for higher-grade tumors or those where the initial resection was incomplete. Effective management of meningioma, therefore, is characterized by a long-term commitment to monitoring, early detection of recurrence, and prompt re-intervention when signs of disease progression are observed.

Further Reading

• Meningioma (Wikipedia)
• Meningioma: An Overview of Diagnosis and Treatment Strategies (NCBI)
• American Association of Neurological Surgeons (AANS) – Meningiomas